Mauritianin

Mauritianin

SCHEMBL572331

CC1O[C@@H](OC2C(O)[C@H](O)C(CO[C@@H]3OC(C)[C@H](O)[C@H](O)C3O)O[C@H]2Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H](O)C(O)[C@H]1O

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 5/20 0.88
▸ POLB P06746 3/20 0.88
▸ GAA P10253 3/20 0.88
▸ XDH P47989 2/20 0.88
▸ APEX1 P27695 2/20 0.88
▸ RECQL P46063 2/20 0.88
▸ L3MBTL1 Q9Y468 2/20 0.88
▸ KDM4E B2RXH2 4/20 0.78
▸ MAPT P10636 2/20 0.78
▸ HES1 Q14469 2/20 0.78
▸ FANCF Q9NPI8 2/20 0.78
▸ KDM1A O60341 1/20 0.78
▸ PRSS1 P07477 1/20 0.78
▸ PRSS2 P07478 1/20 0.78
▸ ADRA2A P08913 1/20 0.78
▸ HMGB1 P09429 1/20 0.78
▸ CFTR P13569 1/20 0.78
▸ ADRA2C P18825 1/20 0.78
▸ MAOA P21397 1/20 0.78
▸ ACHE P22303 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mauritianin SCHEMBL30003610 1.00 P4HB (0.88) P4HBPOLBGAAXDHAPEX1
Mauritianin SCHEMBL3746601 1.00 P4HB (0.88) P4HBPOLBGAAXDHAPEX1
Mauritianin SCHEMBL572330 1.00 P4HB (0.88) P4HBPOLBGAAXDHAPEX1
Mauritianin SCHEMBL18167030 1.00 P4HB (0.88) P4HBPOLBGAAXDHAPEX1
SCHEMBL29436868 0.98 P4HB (0.84) P4HBPOLBGAAXDHAPEX1
Camelliaside A SCHEMBL29882538 0.97 P4HB (0.83) P4HBPOLBGAAXDHAPEX1
Camelliaside A SCHEMBL14813695 0.97 P4HB (0.83) P4HBPOLBGAAXDHAPEX1
Camelliaside A SCHEMBL13328501 0.97 P4HB (0.83) P4HBPOLBGAAXDHAPEX1
Camelliaside A SCHEMBL30637486 0.97 P4HB (0.83) P4HBPOLBGAAXDHAPEX1
SCHEMBL22678451 0.97 P4HB (0.88) P4HBPOLBGAAXDHAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119639835-A Preparation method of keemun camellia seed fermented oil 广州中妆美业化妆品有限公司 2025-03-18 — — CN disclosed
CN-104222378-B A kind of health care complex tea and preparation method thereof 贵州凤冈县仙人岭锌硒有机茶业有限公司 2016-08-17 — — CN disclosed
CN-105288516-A Traditional Chinese medicine composition for treating chronic cholecystitis LU ZHONGXIN 2016-02-03 — — CN disclosed
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 — — US disclosed
CN-104222378-A Health compound tea and preparation method thereof GUIZHOU FENGGANG XIANRENLING ZINC & SELENIUM ORGANIC TEA INDUSTRY CO LTD 2014-12-24 — — CN disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 — — US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 — — US disclosed
US-20140155961-A1 METHODS OF TREATING SKIN Tracie Martyn International, Inc. (US) 2014-06-05 — — US disclosed
EP-2598150-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS The Hospital For Sick Children (CA) 2013-06-05 — — EP disclosed
WO-2012018643-A2 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2012-02-09 — — WO disclosed
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2011-12-08 — — US disclosed
US-20100272790-A1 Methods of Treating Skin TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-10-28 — — US disclosed
US-7776915-B2 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-08-17 — — US disclosed
WO-2010039679-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2010-04-08 — — WO disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155961-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT P4HB 3344/4885POLB 1760/4885GAA 907/4885
US-20100272790-A1 Methods of Treating Skin CUTA, LIPA, DLAT P4HB 3344/4885POLB 1760/4885GAA 907/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT P4HB 3344/4885POLB 1760/4885GAA 907/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A P4HB 3841/4885POLB 1930/4885GAA 1450/4885
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 P4HB 3209/4885POLB 292/4885GAA 3295/4885
US-20110301105-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 P4HB 3209/4885POLB 292/4885GAA 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback